ArticleChemistry & biodiversity2026
Sulfated Alfalfa Polysaccharides Enhance Post-Obesity Recovery Through Modulation of Gut Microbiota and Antioxidant Activity.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Alfalfa polysaccharides (APs) and sulfated alfalfa polysaccharides (SAPs) have both demonstrated efficacy in mitigating obesity. This study was designed to explore the physiological modifications and the mechanisms underlying these changes in obese mice treated with APs and SAPs following a dietary transition. Obese mice underwent treatment with orlistat, APs, and SAPs for 2 months, after which the treatments were discontinued, and their high-fat diet was substituted with a basal diet. Subsequent evaluations were conducted to assess various physiological changes. Our results indicated that dietary modification led to normalization of feed intake and serum triglyceride levels in mice treated with APs and SAPs. Compared to mice treated with orlistat and those that remained untreated, mice receiving APs and SAPs exhibited significantly improved liver antioxidant capacity and immune function. Moreover, treatment with Orlistat, APs, and SAPs resulted in a reduction in intestinal permeability, achieved by enhancing colonic short-chain fatty acid levels and upregulating the expression of tight junction proteins in the colon. Treatments induced significant alterations in the colonic microbial community of the mice, which was characterized by an increased relative abundance of Bifidobacteria and a decreased Firmicutes-to-Bacteroidetes (F/B) ratio across all treatment groups. The most significant decrease in the F/B ratio was observed in the mice treated with SAPs. Our study indicates that, treatments with APs and SAPs improved antioxidant capacity and immune function in obese mice following dietary changes. In addition, APs and SAPs induced long-lasting alterations in the structure of the gut microbial community, which favored rapid health improvement.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.